Status:
COMPLETED
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Huntington Society of Canada
Huntington Study Group
Conditions:
Huntington Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Huntington disease is characterized by difficulties in movement and thinking. Psychological disturbances including irritability, aggression, loss of interest, depressed mood, obsessions and compulsion...
Detailed Description
TRACK-HD was a multi-centre, multi-national, prospective, observational study of pre-manifest and early Huntington's disease (HD) with a control group of volunteers not carrying the HD mutation. The g...
Eligibility Criteria
Inclusion
- To be eligible for the study, a subject must be enrolled in the early HD cohort of the TRACK-HD study and:
- be at least 18 years of age and not older than 65
- able to provide written consent
- carry the abnormal HD gene and show early symptoms of HD
- be able and willing to comply with study requirements, including travel to study center
- have no metal implants to be suitable for MRI scans and able to tolerate them
- able to tolerate blood draws
- be of stable medical, psychiatric and neurological health at the time of enrollment
- not have a history of significant head injury
- not have a history of significant hand injury that would prevent either writing or performing rapid computer tasks
- not be abusing drugs and/or alcohol that may cause failure to comply with study procedures
- not be currently participating in PREDICT-HD or a clinical drug trial.
Exclusion
- Prospective subjects will be excluded if:
- they are younger than 18 years of age and older than 65
- they are unable to provide written consent
- they show advanced symptoms of HD if they are HD gene carriers
- they are unwilling to comply with study requirements, including travel to study center
- they are unsuitable for MRI (e.g, claustrophobia, metal implants) or unable to tolerate them
- they are unable to tolerate blood draws; or,
- they have a major psychiatric disorder, concomitant significant neurological disorder or concomitant significant medical illness at the time of enrollment
- they have a history of CNS disease or significant head injury; or,
- they have a history of significant hand injury that would prevent either writing or performing rapid computer tasks; or,
- they are likely to be non-compliant with study procedures due to drug and/or alcohol abuse; or,
- they are participating in PREDICT-HD or a clinical drug trial at the time of enrollment.
- they are not sighted
- English is not their first language
- they are currently or treated within the last 6 months with antipsychotic medications, including the traditional neuroleptics such as haloperidol as well as the atypical antipsychotics risperidone, clozapine, quetiapine and olanzapine
- they are use phenothiazine-derivative antiemetic medications such as prochlorperazine, metoclopramide, promethazine and Inapsine on a regular basis (greater than 3 times per month)
- they have a history of learning disability and/or mental retardation.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01458470
Start Date
September 1 2011
End Date
November 1 2012
Last Update
January 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Centre for Huntington Disease
Vancouver, British Columbia, Canada, V6T 2B5